MA30768B1 - Methodes d'administration d'agents hypoglycemiques a longue duree d'action - Google Patents

Methodes d'administration d'agents hypoglycemiques a longue duree d'action

Info

Publication number: MA30768B1
Authority: MA; Morocco
Prior art keywords: methods; action; long term; hypoglycemic agents; administering
Prior art date: 2006-09-13

Application number

MA31741A

Other languages

English (en)

French (fr)

Inventor

Mark A Bush

Jessica E Matthews

Susan E Walker

Original Assignee

Smithkline Beecham Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2006-09-13

Filing date

2009-03-30

Publication date

2009-10-01

2009-03-30 Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp

2009-10-01 Publication of MA30768B1 publication Critical patent/MA30768B1/fr

Links

239000003472 antidiabetic agent Substances 0.000 title abstract 3
229940126904 hypoglycaemic agent Drugs 0.000 title abstract 3
230000007774 longterm Effects 0.000 title 1
102100025101 GATA-type zinc finger protein 1 Human genes 0.000 abstract 1
101710198884 GATA-type zinc finger protein 1 Proteins 0.000 abstract 1
DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 1
239000000556 agonist Substances 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/38—Albumins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Epidemiology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Organic Chemistry (AREA)
Diabetes (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Emergency Medicine (AREA)
Hematology (AREA)
Hospice & Palliative Care (AREA)
Obesity (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

MA31741A 2006-09-13 2009-03-30 Methodes d'administration d'agents hypoglycemiques a longue duree d'action MA30768B1 (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US82547206P	2006-09-13	2006-09-13
US86839106P	2006-12-04	2006-12-04

Publications (1)

Publication Number	Publication Date
MA30768B1 true MA30768B1 (fr)	2009-10-01

Family

ID=39184534

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA31741A MA30768B1 (fr)	2006-09-13	2009-03-30	Methodes d'administration d'agents hypoglycemiques a longue duree d'action

Country Status (25)

Country	Link
US (3)	US8338369B2 (ar)
EP (1)	EP2073834B1 (ar)
JP (2)	JP5524620B2 (ar)
KR (1)	KR101472601B1 (ar)
CN (1)	CN103705911A (ar)
AR (1)	AR062775A1 (ar)
AU (1)	AU2007296499C1 (ar)
BR (1)	BRPI0716765A8 (ar)
CA (1)	CA2662622C (ar)
CL (1)	CL2007002634A1 (ar)
CR (1)	CR10684A (ar)
EA (1)	EA017159B1 (ar)
ES (1)	ES2442869T3 (ar)
IL (1)	IL197448A (ar)
JO (1)	JO2945B1 (ar)
MA (1)	MA30768B1 (ar)
MX (1)	MX2009002863A (ar)
MY (1)	MY149911A (ar)
NO (1)	NO20091266L (ar)
NZ (1)	NZ575419A (ar)
PE (2)	PE20080840A1 (ar)
SG (2)	SG10201501749WA (ar)
TW (1)	TWI430806B (ar)
WO (1)	WO2008033888A2 (ar)
ZA (1)	ZA200901548B (ar)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL1965823T3 (pl)	2005-11-04	2017-08-31	Glaxosmithkline Llc	Sposoby podawania środków hipoglikemicznych
HUE031900T2 (en) *	2008-12-10	2017-08-28	Glaxosmithkline Llc	Pharmaceutical compositions containing Albiglutide
EP2566502A4 (en) *	2010-05-04	2013-10-09	Glaxosmithkline Llc	METHODS OF TREATING OR PREVENTING CARDIOVASCULAR DISORDERS AND PROVIDING CARDIOVASCULAR PROTECTION
MX377589B (es)	2010-12-16	2025-03-10	Novo Nordisk As	Composiciones sólidas que comprenden agonista de glp-1 y sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico.
AU2012241894B2 (en)	2011-04-12	2015-12-03	Novo Nordisk A/S	Double-acylated GLP-1 derivatives
KR102072202B1 (ko)	2012-03-22	2020-01-31	노보 노르디스크 에이/에스	Ｇｌｐ-1 펩티드의 조성물 및 그것의 제조
ES2715308T3 (es)	2012-03-22	2019-06-03	Novo Nordisk As	Composiciones que comprenden un agente de suministro y su preparación
WO2013189988A1 (en)	2012-06-20	2013-12-27	Novo Nordisk A/S	Tablet formulation comprising a peptide and a delivery agent
RS58039B1 (sr)	2013-05-02	2019-02-28	Novo Nordisk As	Oralno doziranje glp-1 jedinjenja
DK3004155T3 (da)	2013-05-28	2022-01-03	Takeda Pharmaceuticals Co	Peptidforbindelse
EP3467106B1 (en)	2016-05-24	2025-07-09	Takeda Pharmaceutical Company Limited	Peptide compound
AR114353A1 (es)	2018-02-02	2020-08-26	Novo Nordisk As	Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico
TW202423476A (zh) *	2021-03-23	2024-06-16	美商美國禮來大藥廠	含腸促胰島素(incretin)類似物之組合物及其用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5545618A (en)	1990-01-24	1996-08-13	Buckley; Douglas I.	GLP-1 analogs useful for diabetes treatment
US5512549A (en) *	1994-10-18	1996-04-30	Eli Lilly And Company	Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
DE69740096D1 (de) *	1996-08-08	2011-02-17	Amylin Pharmaceuticals Inc	Pharmazeutische Zusammensetzung mit einem Exendin-4-Peptid
US6277819B1 (en) *	1996-08-30	2001-08-21	Eli Lilly And Company	Use of GLP-1 or analogs in treatment of myocardial infarction
US6380357B2 (en) *	1997-12-16	2002-04-30	Eli Lilly And Company	Glucagon-like peptide-1 crystals
CO5090908A1 (es) *	1998-08-28	2001-10-30	Lilly Co Eli	Procedimiento para administrar peptidos insulinotropicos
PT1180121E (pt) *	1999-05-17	2004-03-31	Conjuchem Inc	Peptidos insulinotropicos de longa duracao
US6395767B2 (en) *	2000-03-10	2002-05-28	Bristol-Myers Squibb Company	Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
SI1724284T1 (sl) *	2000-12-07	2009-12-31	Lilly Co Eli	Glp-1 fuzijski proteini
AU2002239384B2 (en) *	2000-12-13	2007-01-11	Eli Lilly And Company	Chronic treatment regimen using glucagon-like insulinotropic peptides
JP2005506956A (ja) *	2001-06-01	2005-03-10	イーライ・リリー・アンド・カンパニー	長時間作用性ｇｌｐ−１製剤
AU2002322403A1 (en) *	2001-08-23	2003-03-10	Eli Lilly And Company	Glucagon-like peptide-1 analogs
AR036711A1 (es)	2001-10-05	2004-09-29	Bayer Corp	Peptidos que actuan como agonistas del receptor del glp-1 y como antagonistas del receptor del glucagon y sus metodos de uso farmacologico
GEP20063908B (en)	2001-10-18	2006-08-25	Bristol Myers Squibb Co	Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
CA2841097A1 (en) *	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin and g-csf fusion proteins
WO2005003296A2 (en) *	2003-01-22	2005-01-13	Human Genome Sciences, Inc.	Albumin fusion proteins
WO2003059934A2 (en) *	2001-12-21	2003-07-24	Human Genome Sciences, Inc.	Albumin fusion proteins
AR038102A1 (es)	2002-01-08	2004-12-29	Lilly Co Eli	Analogos extendidos de peptido 1 de tipo glucagon
AU2004288831B2 (en) *	2003-11-12	2010-08-26	Phenomix Corporation	Heterocyclic boronic acid compounds
EP1704998B1 (en) *	2004-01-13	2011-04-20	Asahi Glass Company, Limited	Multilayer laminate
CN102816241B (zh) *	2004-02-09	2015-07-22	人类基因科学公司	清蛋白融合蛋白
US8410047B2 (en)	2004-06-11	2013-04-02	Novo Nordisk A/S	Counteracting drug-induced obesity using GLP-1 agonists
PL1965823T3 (pl) *	2005-11-04	2017-08-31	Glaxosmithkline Llc	Sposoby podawania środków hipoglikemicznych
EP2021014A1 (en)	2006-05-26	2009-02-11	Brystol-Myers Squibb Company	Sustained release glp-1 receptor modulators

2007
- 2007-09-11 JO JO2007382A patent/JO2945B1/ar active
- 2007-09-11 TW TW096133808A patent/TWI430806B/zh not_active IP Right Cessation
- 2007-09-11 CL CL200702634A patent/CL2007002634A1/es unknown
- 2007-09-11 PE PE2007001215A patent/PE20080840A1/es not_active Application Discontinuation
- 2007-09-11 PE PE2012001061A patent/PE20121528A1/es not_active Application Discontinuation
- 2007-09-12 ES ES07842306.8T patent/ES2442869T3/es active Active
- 2007-09-12 KR KR1020097007414A patent/KR101472601B1/ko not_active Expired - Fee Related
- 2007-09-12 SG SG10201501749WA patent/SG10201501749WA/en unknown
- 2007-09-12 SG SG2011063856A patent/SG174770A1/en unknown
- 2007-09-12 MY MYPI20090993A patent/MY149911A/en unknown
- 2007-09-12 AR ARP070104049A patent/AR062775A1/es not_active Application Discontinuation
- 2007-09-12 US US12/441,152 patent/US8338369B2/en not_active Expired - Fee Related
- 2007-09-12 BR BRPI0716765A patent/BRPI0716765A8/pt not_active Application Discontinuation
- 2007-09-12 NZ NZ575419A patent/NZ575419A/en not_active IP Right Cessation
- 2007-09-12 CA CA2662622A patent/CA2662622C/en not_active Expired - Fee Related
- 2007-09-12 JP JP2009528440A patent/JP5524620B2/ja active Active
- 2007-09-12 MX MX2009002863A patent/MX2009002863A/es active IP Right Grant
- 2007-09-12 CN CN201410014248.3A patent/CN103705911A/zh active Pending
- 2007-09-12 AU AU2007296499A patent/AU2007296499C1/en not_active Ceased
- 2007-09-12 EA EA200970274A patent/EA017159B1/ru not_active IP Right Cessation
- 2007-09-12 EP EP07842306.8A patent/EP2073834B1/en active Active
- 2007-09-12 WO PCT/US2007/078226 patent/WO2008033888A2/en not_active Ceased
2009
- 2009-03-04 ZA ZA2009/01548A patent/ZA200901548B/en unknown
- 2009-03-05 IL IL197448A patent/IL197448A/en active IP Right Grant
- 2009-03-23 CR CR10684A patent/CR10684A/es not_active Application Discontinuation
- 2009-03-26 NO NO20091266A patent/NO20091266L/no not_active Application Discontinuation
- 2009-03-30 MA MA31741A patent/MA30768B1/fr unknown
2012
- 2012-06-12 US US13/494,253 patent/US20130005652A1/en not_active Abandoned
2013
- 2013-07-19 US US13/946,296 patent/US20140066371A1/en not_active Abandoned
2014
- 2014-04-10 JP JP2014081275A patent/JP5753924B2/ja not_active Expired - Fee Related

Also Published As

Publication number	Publication date
US20100009910A1 (en)	2010-01-14
PE20080840A1 (es)	2008-08-27
JP5524620B2 (ja)	2014-06-18
JP2010503697A (ja)	2010-02-04
KR101472601B1 (ko)	2014-12-15
US8338369B2 (en)	2012-12-25
IL197448A0 (en)	2011-08-01
CR10684A (es)	2009-04-28
TWI430806B (zh)	2014-03-21
MX2009002863A (es)	2009-03-30
BRPI0716765A2 (pt)	2013-09-24
US20140066371A1 (en)	2014-03-06
EA200970274A1 (ru)	2009-08-28
AU2007296499B2 (en)	2013-05-02
CA2662622A1 (en)	2008-03-20
ES2442869T3 (es)	2014-02-14
PE20121528A1 (es)	2012-12-12
WO2008033888A2 (en)	2008-03-20
CA2662622C (en)	2017-01-17
JO2945B1 (ar)	2016-03-15
IL197448A (en)	2013-06-27
SG10201501749WA (en)	2015-05-28
US20130005652A1 (en)	2013-01-03
CN103705911A (zh)	2014-04-09
KR20090059155A (ko)	2009-06-10
AU2007296499A1 (en)	2008-03-20
ZA200901548B (en)	2010-02-24
NZ575419A (en)	2011-11-25
WO2008033888A3 (en)	2008-10-16
JP5753924B2 (ja)	2015-07-22
EA017159B1 (ru)	2012-10-30
MY149911A (en)	2013-10-31
BRPI0716765A8 (pt)	2017-02-21
AR062775A1 (es)	2008-12-03
JP2014148524A (ja)	2014-08-21
TW200824706A (en)	2008-06-16
CL2007002634A1 (es)	2008-05-16
EP2073834A4 (en)	2010-11-03
NO20091266L (no)	2009-06-09
EP2073834B1 (en)	2013-10-23
AU2007296499C1 (en)	2013-09-12
SG174770A1 (en)	2011-10-28
EP2073834A2 (en)	2009-07-01

Publication	Publication Date	Title
EA200970274A1 (ru)	2009-08-28	Способы введения гипогликемических средств с длительным действием
CO6440528A2 (es)	2012-05-15	Composiciones adyuvantes que comprenden un agente de isotonicidad no iónico.
ATE275967T1 (de)	2004-10-15	Verwendung von exendinen und deren agonisten zur behandlung von hypertriglyceridämie
HUP0301405A2 (hu)	2003-08-28	Fokozott oldékonyságú gyógyhatású komponenseket tartalmazó készítmények
WO2009109927A3 (en)	2010-02-25	Glp-1 receptor agonists and related active pharmaceutical ingredients for treatment of cancer
AR047841A1 (es)	2006-03-01	Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios
GT200600004A (es)	2006-09-11	Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentracion sanguinea de glp-1
CY1107752T1 (el)	2013-04-18	Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
ECSP088239A (es)	2008-04-28	Composición de liberación de fármaco sostenida
DE602006014990D1 (de)	2010-07-29	Intranasale verabreichung von schnell wirkendem insulin
AR043258A1 (es)	2005-07-20	Formulacion, complejo antiacido omeprazol - liberacion inmediata, para supresion rapida y sostenida de la acidez gastrica
AR060306A1 (es)	2008-06-04	Terapia de combinacion de anticuerpos contra ctla4
AR046811A1 (es)	2005-12-28	Formas de dosificacion oral de ziprasidona de liberacion sostenida
CL2009000985A1 (es)	2010-01-15	Composicion oftalmica que comprende entre 0,16 y 0,19% p/v de un galactomanano, alrededor de 0,7% p/v de un borato, cis-diol y menos de 5 ppm de concentracion de cationes divalentes; y su uso para lubricar el ojo.
MX2010005013A (es)	2010-05-27	Composiciones intranasales.
ECSP088240A (es)	2008-04-28	Composición de trazodona para administración una vez por día
WO2006089114A3 (en)	2007-01-11	Methods and compositions for treating an anthrax toxin mediated condition
EA200800950A1 (ru)	2008-08-29	Способы лечения и профилактики среднего отита с применением неионных поверхностно-активных веществ для облегчения трансмембранного введения лекарственного средства в среднее ухо
AR072951A1 (es)	2010-10-06	Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
WO2008128191A3 (en)	2009-01-15	Oral cephalotaxine dosage forms
CL2009000986A1 (es)	2010-12-31	Uso de inhibidores de pai-1 para la p0reparacion de un medicamento util en el tratamiento de hipertension ocular y glaucoma
AR061155A1 (es)	2008-08-06	Preparaciones liofilizadas de pantoprazol sodico para inyeccion
PE20030277A1 (es)	2003-03-25	Composicion farmaceutica que comprende 2-[5-(4-fluorofenil)-3-piridilmetilaminometil]-cromano y l-dopa
WO2007056236A3 (en)	2007-09-20	Methods of treating cancer with lipid-based platinum compound formulations administered intravenously
CL2008003292A1 (es)	2010-01-11	Hidrato cristalino de hidrocloruro de r-6-hidroxi-8-{1-hidroxi-2-[2-(4-metoxi-fenil)-1,1-dimetil-etilamino]-etil}-4h-benzo[1,4]oxazin-3-ona; composicion y combinacion farmaceutica que lo comprende; preparacion de una solucion inhalable que lo comprende; y uso en el tratamiento de dolencias respiratorias.